VBWG
Slides

Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial



Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial

Download VBWG06_DREAM.ppt (22 slides - 0.9MB)

Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial Worldwide prevalence of diabetes expected to increase  		DECODE: IGT increases mortality risk DPP: Benefit of diet + exercise or metformin on diabetes prevention in at-risk patients TZDs: Focus on PPAR activation TRIPOD: Treating insulin resistance reduces incidence of type 2 diabetes TZDs blunt diabetes progression Potential antidiabetic mechanisms of ACE inhibition HOPE, EUROPA, PEACE: Reduction in new-onset diabetes (placebo-controlled trials) DREAM: Study design DREAM: 2 × 2 factorial design DREAM: Baseline characteristics DREAM: Rosiglitazone effect on primary outcome DREAM: Rosiglitazone decreases new-onset diabetes or death DREAM: Effect of rosiglitazone on primary outcome in key subgroups DREAM: Conversion to normoglycemia with rosiglitazone Rosiglitazone effect on weight and BMI Rosiglitazone effect on waist and hip measurements DREAM: Ramipril effect on primary outcome DREAM: Ramipril effects on glycemic categories DREAM: Safety DREAM results: Summary


DiabetesDREAMMedicationramiprilrosiglitazone

Related at vwbg.org

Managing CV Risk in Diabetes: Setting More Aggressive Goals to Meet a Growing Crisis

The evolving diabetes epidemic is raising concern over the adverse long-term effect on cardiovascular (CV) disease.

ADOPT: A Diabetes Outcome Progression Trial

View/Download individual slides (15 Slides)

RIO-Diabetes trial: Rimonabant In Obesity

View/Download individual slides (13 Slides)
More related